|
1
|
Lowenfels AB: Why are small-bowel tumours
so rare? Lancet. 1:24–26. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dabaja BS, Suki D, Pro B, Bonnen M and
Ajani J: Adenocarcinoma of the small bowel: Presentation,
prognostic factors and outcome of 217 patients. Cancer.
101:518–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mishkin DS, Chuttani R, Croffie J, Disario
J, Liu J, Shah R, Somogyi L, Tierney W, Song LM and Petersen BT;
Technology Assessment Committee, American Society for
Gastrointestinal Endoscopy, : ASGE technology status evaluation
report: Wireless capsule endoscopy. Gastrointest Endosc.
63:539–545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto H, Sekine Y, Sato Y, Higashizawa
T, Miyata T, Iino S, Ido K and Sugano K: Total enteroscopy with a
nonsurgical steerable double-balloon method. Gastrointest Endosc.
53:216–220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto H, Yano T, Kita H, Sunada K, Ido
K and Sugano K: New system of double-balloon enteroscopy for
diagnosis and treatment of small intestinal disorders.
Gastroenterology. 125:1556–1557. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chow JS, Chen CC, Ahsan H and Neugut AI: A
population-based study of the incidence of malignant small bowel
tumours: SEER, 1973–1990. Int J Epidemiol. 25:722–728. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hatzaras I, Palesty JA, Abir F, Sullivan
P, Kozol RA, Dudrick SJ and Longo WE: Small-bowel tumors:
Epidemiologic and clinical characteristics of 1260 cases from the
connecticut tumor registry. Arch Surg. 142:229–235. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ouriel K and Adams JT: Adenocarcinoma of
the small intestine. Am J Surg. 147:66–71. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barnes G Jr, Romero L, Hess KR and Curley
SA: Primary adenocarcinoma of the duodenum: Management and survival
in 67 patients. Ann Surg Oncol. 1:73–78. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bauer RL, Palmer ML, Bauer AM, Nava HR and
Douglass HO Jr: Adenocarcinoma of the small intestine: 21-year
review of diagnosis, treatment, and prognosis. Ann Surg Oncol.
1:183–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rose DM, Hochwald SN, Klimstra DS and
Brennan MF: Primary duodenal adenocarcinoma: A ten-year experience
with 79 patients. J Am Coll Surg. 183:89–96. 1996.PubMed/NCBI
|
|
13
|
Raghav K and Overman MJ: Small bowel
adenocarcinomas-existing evidence and evolving paradigms. Nat Rev
Clin Oncol. 10:534–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haan JC, Buffart TE, Eijk PP, van de Wiel
MA, van Wieringen WN, Howdle PD, Mulder CJ, van de Velde CJ, Quirke
P, Nagtegaal ID, et al: Small bowel adenocarcinoma copy number
profiles are more closely related to colorectal than to gastric
cancers. Ann Oncol. 23:367–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zaanan A, Costes L, Gauthier M, Malka D,
Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, et
al: Chemotherapy of advanced small-bowel adenocarcinoma: A
multicenter AGEO study. Ann Oncol. 21:1786–1793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Wang LY, Deng YM, Wang FH, Feng
F, Chen YC, An X, Chen C, Xu RH and Li YH: Efficacy of the
FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: A
three-center study from China. J BUON. 16:689–696. 2011.PubMed/NCBI
|
|
17
|
Tsushima T, Taguri M, Honma Y, Takahashi
H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F, et al:
Multicenter retrospective study of 132 patients with unresectable
small bowel adenocarcinoma treated with chemotherapy. Oncologist.
17:1163–1170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Overman MJ, Varadhachary GR, Kopetz S,
Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL and Wolff RA:
Phase II study of capecitabine and oxaliplatin for advanced
adenocarcinoma of the small bowel and ampulla of Vater. J Clin
Oncol. 27:2598–2603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F,
Zhan ZY, Feng M, Yan J, Zhao JG and Xiong JP: A phase II study of
modified FOLFOX as first-line chemotherapy in advanced small bowel
adenocarcinoma. Anticancer Drugs. 23:561–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsang H, Yau T, Khong PL and Epstein RJ:
Bevacizumab-based therapy for advanced small bowel adenocarcinoma.
Gut. 57:1631–1632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okubo K, Yoshioka S, Asukai K, Hata T,
Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie
M, et al: A case report of primary adenocarcinoma of small
intestine. Gan To Kagaku Ryoho. 37:2792–2794. 2010.(In Japanese).
PubMed/NCBI
|
|
23
|
Nagaraj G, Zarbalian Y, Flora K and Tan BR
Jr: Complete response and prolonged disease-free survival in a
patient with recurrent duodenal adenocarcinoma treated with
bevacizumab plus FOLFOX6. J Gastrointest Oncol. 5:E1–E6.
2014.PubMed/NCBI
|
|
24
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Institutes of health national
cancer institute, . Common Terminology criteria for adverse events
(CTCAE) Version 4.0. U.S. Department of Health and Human Services;
2009
|
|
27
|
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY,
Bennett CL and Talamonti MS: Small bowel cancer in the United
States: Changes in epidemiology, treatment, and survival over the
last 20 years. Ann Surg. 249:63–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Overman MJ, Pozadzides J, Kopetz S, Wen S,
Abbruzzese JL, Wolff RA and Wang H: Immunophenotype and molecular
characterisation of adenocarcinoma of the small intestine. Br J
Cancer. 102:144–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aparicio T, Svrcek M, Zaanan A, Beohou E,
Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, et
al: Small bowel adenocarcinoma phenotyping, a clinicobiological
prognostic study. Br J Cancer. 109:3057–3066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zaanan A, Gauthier M, Malka D, Locher C,
Gornet JM, Thirot-Bidault A, Tougeron D, Taïeb J, Bonnetain F and
Aparicio T; Association des Gastro Entérologues Oncologues, :
Second-line chemotherapy with fluorouracil, leucovorin, and
irinotecan (FOLFIRI regimen) in patients with advanced small bowel
adenocarcinoma after failure of first-line platinum-based
chemotherapy: A multicenter AGEO study. Cancer. 117:1422–1428.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dvorak HF: Vascular permeability
factor/vascular endothelial growth factor: A critical cytokine in
tumor angiogenesis and a potential target for diagnosis and
therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Willett CG, Boucher Y, di Tomaso E, Duda
DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et
al: Direct evidence that the VEGF-specific antibody bevacizumab has
antivascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chien CR Chang, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
de Dosso S, Molinari F, Martin V, Frattini
M and Saletti P: Molecular characterisation and cetuximab-based
treatment in a patient with refractory small bowel adenocarcinoma.
Gut. 59:1587–1588. 2010. View Article : Google Scholar : PubMed/NCBI
|
